Elisa Gobbini

26 Rue D'Ulm, Paris Cedex 05
Paris, 75248, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Journal: Oncology and therapy

Published: March 06, 2026

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.

Journal: ESMO open

Published: January 29, 2026

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.

Journal: Cancer research

Published: December 31, 2025

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer.

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer.

Journal: Cancer research communications

Published: December 27, 2025

Dendritic cells: the central partner for cancer immunity.

Dendritic cells: the central partner for cancer immunity.

Journal: Oncoimmunology

Published: November 14, 2025

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 05, 2025

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Journal: Oncology and therapy

Published: July 22, 2025

Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".

Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 11, 2025

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 28, 2025

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 21, 2025

First line pembrolizumab plus chemotherapy in unresectable pleural mesothelioma

First line pembrolizumab plus chemotherapy in unresectable pleural mesothelioma

Journal: Bulletin du cancer

Published: February 11, 2025

Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.

Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 28, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026